



## Amina Chaudhry, MD

Clinical Assistant Professor, Medicine - Oncology

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

900 Blake Wilbur Dr

3rd Fl

Stanford, CA 94305

**Tel** (650) 498-6000      **Fax** (650) 498-8797

### Bio

---

#### BIO

Dr. Amina Chaudhry is a medical oncologist in the Division of Oncology at Stanford University School of Medicine. As part of Stanford University's Breast Cancer Program, she specializes in treating patients diagnosed with breast cancer.

Dr. Chaudhry completed a residency in internal medicine at the University of Tennessee Health Science Center. She gained advanced training in hematology and oncology through a fellowship at University of Illinois Chicago. She is certified by the American Board of Internal Medicine.

Dr. Chaudhry's research focuses on improving outcomes in disadvantaged populations with breast cancer. In 2022, she received the Repurposing Research to Address Diversity, Equity, and Inclusion grant to support underrepresented patients with early-stage breast cancer.

Dr. Chaudhry has published research in journals including Annals of Oncology, Journal of Clinical Oncology, and Blood Advances. She has presented her work at the annual meetings of the American Society of Clinical Oncology (ASCO), San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH).

Dr. Chaudhry has a strong interest in tackling healthcare inequities and improving access to clinical trials.

#### CLINICAL FOCUS

- Oncology

#### ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology

#### HONORS AND AWARDS

- Best in Research Fellow Award, University of Illinois Chicago

- Repurposing Research to Address Diversity, Equity, and Inclusion in the Greater Chicago Area grant, Cures Within Reach
- First Place, Best Abstract – Resident Category, Medicine in Research Award, Alpha Omega Alpha
- Doctoral Undergraduate Opportunity Scholarship (DUOS) research grant in microbiology, Miami University

## PROFESSIONAL EDUCATION

- Board Certification: Hematology, American Board of Internal Medicine (2023)
- Board Certification: Oncology, American Board of Internal Medicine (2023)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2020)
- Fellowship: University of Illinois Hematology and Medical Oncology Fellowship (2023) IL
- Residency: Univ of Tennessee Health Sciences Internal Medicine Residency (2020) TN
- Medical Education: Ross University School of Medicine (2017) FL

## Publications

---

### PUBLICATIONS

- **High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series.** *Blood advances*  
Epperla, N., Zayac, A. S., Landsburg, D. J., Bock, A. M., Nowakowski, G. S., Ayers, E. C., Girton, M. R., Hu, M., Beckman, A. K., Li, S., Medeiros, L. J., Chang, J. E., Kurt, et al  
2024
- **Assessing the feasibility and cost-effectiveness of all oral adjuvant chemotherapy (cyclophosphamide, methotrexate, capecitabine) in high-risk hormone receptor positive breast cancer**  
Ibraheem, A., Gadi, V. K., Hoskins, K., Chaudhry, A.  
LIPPINCOTT WILLIAMS & WILKINS.2024
- **High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series** *Blood Advances*  
Epperla, N., Zayac, A. S., Landsburg, D. J., Bock, A. M., Nowakowski, G. S., Ayers, E. C., Rubinstein, P. G., Amina, C., Olszewski, A. J.  
2024
- **Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients.** *Current oncology reports*  
Puri, S., Chaudhry, A., Bayable, A., Ganesh, A., Daher, A., Gadi, V. K., Maraka, S.  
2023
- **High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.** *Blood advances*  
Zayac, A. S., Landsburg, D. J., Hughes, M. E., Bock, A. M., Nowakowski, G. S., Ayers, E. C., Girton, M. R., Hu, M., Beckman, A. K., Li, S., Medeiros, L. J., Chang, J. E., Stepanovic, et al  
2023
- **Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.** *BMC cancer*  
Ranganath, H., Jain, A. L., Smith, J. R., Ryder, J., Chaudry, A., Miller, E., Hare, F., Valasareddy, P., Seitz, R. S., Hout, D. R., Varga, M. G., Schweitzer, B. L., Nielsen, et al  
2022; 22 (1): 407
- **Analysis of germline mutations in malignancies with concurrent pathogenic mutations in BRCA1, BRCA2, PALB2, ATM, CHEK2, and RAD51C/D**  
Chaudhry, A., Jain, A., Mullins, J., Hare, F., Valasareddy, P., Ranganath, V.  
Annals of Oncology.  
2021
- **Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancer**  
Jain, A., Chaudhry, A., Schwartzberg, L., Vidal, G.  
Proc (Baylor Univ Med Cent).  
2020

- **Unusual Case Of A Recurrent Metastasizing Benign Breast Papilloma**

Jain, A., Chaudhry, A., Schwartzberg, L., Vidal, G.  
Journal of Medical Case Reports.  
2020

- **Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR MBC)**

Jain, A., Chaudhry, A., Vidal, G.  
Journal of Clinical Oncology.  
2019

- **Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention**

Chaudhry, A., Shah, R.  
Catheterization and Cardiovascular Interventions.  
2018

- **Bivalirudin versus Heparin without Glycoprotein IIB/IIIA Inhibitors for the Prevention of Stent Thrombosis: A Meta-Analysis**

Shah, R., Chaudhry, A.  
Journal of the American College of Cardiology.  
2018

- **High-volume forced diuresis with matched hydration using the RenalGuard System to prevent contrast-induced nephropathy: A meta-analysis of randomized trials. *Clinical cardiology***

Shah, R., Wood, S. J., Khan, S. A., Chaudhry, A., Rehan Khan, M., Morsy, M. S.  
2017; 40 (12): 1242-1246